Prof. Dr. Mesut Işık is a Professor in the Department of Bioengineering at Bilecik Şeyh Edebali University, Türkiye. His research interests encompass biochemistry, enzymology, biotechnology, bioengineering, and medicinal chemistry. His research focuses on enzyme purification, characterization, kinetics, and immobilization, as well as the development of enzyme-based systems and their potential biotechnological applications. He is also actively involved in natural product research, phytochemical characterization, antioxidant and enzyme inhibitory activities, and the discovery of biologically active compounds. His work integrates experimental biochemical approaches with molecular docking and computational methods to investigate the structure–activity relationships and potential therapeutic applications of bioactive molecules. Through interdisciplinary research, he aims to contribute to advances in biotechnology, drug discovery, and the development of innovative enzyme-based applications. Recognized among Stanford University and Elsevier's World's Top 2% Scientists in the Single-Year Impact category (2021-2026).
Prof. Dr. Mesut Işık is a Professor in the Department of Bioengineering at Bilecik Şeyh Edebali University, Türkiye. His research interests encompass biochemistry, enzymology, biotechnology, bioengineering, and medicinal chemistry. His research focuses on enzyme purification, characterization, kinetics, and immobilization, as well as the development of enzyme-based systems and their potential biotechnological applications. He is also actively involved in natural product research, phytochemical characterization, antioxidant and enzyme inhibitory activities, and the discovery of biologically active compounds. His work integrates experimental biochemical approaches with molecular docking and computational methods to investigate the structure–activity relationships and potential therapeutic applications of bioactive molecules. Through interdisciplinary research, he aims to contribute to advances in biotechnology, drug discovery, and the development of innovative enzyme-based applications. Recognized among Stanford University and Elsevier's World's Top 2% Scientists in the Single-Year Impact category (2021-2026).